Quarterly ibandronate benefits bone

Article

Bone mineral density (BMD) improves through up to 2 years of treatment with IV ibandronate, according to a post hoc analysis presented at the 17th annual meeting of the North American Menopause Society in Nashville, Tenn.

Bone mineral density (BMD) improves through up to 2 years of treatment with IV ibandronate, according to a post hoc analysis presented at the 17th annual meeting of the North American Menopause Society in Nashville, Tenn.

The data were reported by investigators from the DIVA (Dosing IntraVenous Administration) study, phase III comparison of daily oral (2.5 mg) or quarterly IV (3 mg) ibandronate. Nearly 1,400 women aged 55 to 80 who were postmenopausal for at least 5 years were enrolled in the double-blind, double-dummy trial. The post hoc analysis looked only at BMD in women on IV treatment for 1 to 2 years.

BMD at various sites increased from year 1 to year 2, with measurements at the lumbar spine (LS) up nearly 5% and 5.75%, respectively, up 2.21% and 2.44%, respectively, at the femoral neck, up 2.22% and 2.76%, respectively, for total hip, and up 3.6% and 4.48%, respectively, for the trochanter.

Related Videos
Addressing racial and ethnic disparities in brachial plexus birth Injury | Image Credit: shrinerschildrens.org
Innovations in prenatal care: Insights from ACOG 2024 | Image Credit:  uofmhealth.org.
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit: uclahealth.org.
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit: mayo.edu.
raanan meyer, md
New data shows elinzanetant's efficacy in treating menopausal symptoms | Image Credit: uvahealth.com
© 2024 MJH Life Sciences

All rights reserved.